Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: 9 - You Need To See This

3 Gene-Editing Stocks to Buy for Future Health Advances

With ever-expanding operations and rapid technological innovations, the gene-editing industry looks poised for solid long-term growth. Thus, investors could consider solid stocks Eli Lilly (LLY), Sanofi (SNY), and Vertex Pharmaceuticals (VRTX). Continue reading.

Eli Lilly Stock: Analyst Estimates & Ratings

Eli Lilly Stock: Analyst Estimates & Ratings

Eli Lilly has significantly outperformed the broader market over the past year, and Wall Street analysts are bullish about the stock’s prospects.

Stock Market Today: Stocks Rally as Recession Fears Ease

Stock Market Today: Stocks Rally as Recession Fears Ease

Initial jobless claims fell more than expected last week, which helped calm fears of a slowing labor market.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Eli Lilly's Weight-Loss Drugs Fuel Beat-And-Raise Quarter

Eli Lilly stock is surging after the pharma giant beat Q2 estimates and lifted its full-year outlook. Here's what you need to know.

3 Healthcare Innovators With Game-Changing Treatments

The pharmaceutical industry’s long-term growth is fueled by a surge in demand for personalized medicine, rising R&D initiatives, and the adoption of cutting-edge technologies. Hence, it could be ideal to buy fundamentally solid pharma stocks, Eli Lilly (LLY), Bristol-Myers (BMY), and Merck & Co. (MRK), which look poised for blockbuster…

3 Leading S&P 500 Stocks Set to Climb Even Higher

As the stock market evolves, leading S&P 500 stocks like Eli Lilly and Company (LLY), Howmet Aerospace (HWM), and NetApp (NTAP) are well-positioned to capitalize on current market conditions and climb higher. Read on….

What You Need to Know Ahead of Eli Lilly's Earnings Release

As Eli Lilly gears up to release its second-quarter earnings next month, analysts project a double-digit bottom-line growth.

inkl

Read news from The Economist, FT, and more,
with one subscription

3 Pharmaceutical Stocks With Strong Pipelines

3 Pharmaceutical Stocks With Strong Pipelines

The pharmaceutical industry is flourishing due to increasing medical demands and rising healthcare spending worldwide. Hence, pharma stocks Eli Lilly (LLY), Johnson & Johnson (JNJ), and Merck & Co. (MRK), with strong pipelines, might be worth buying. Read more….

3 Mega-Cap Stocks to Consider Before They're Worth $1 Trillion

3 Mega-Cap Stocks to Consider Before They're Worth $1 Trillion

Mega-cap stocks are the flavor of the season, and these three big names are the next set of contenders racing towards the $1 trillion market cap club.

Eli Lilly Stock: Is LLY Outperforming the Healthcare Sector?

Eli Lilly Stock: Is LLY Outperforming the Healthcare Sector?

Eli Lilly has outperformed the healthcare sector over the past three months, but analysts remain cautiously optimistic about the stock’s prospects.

3 Pharma Stocks Poised for Big Returns This Summer

3 Pharma Stocks Poised for Big Returns This Summer

The pharmaceutical industry is expected to grow rapidly due to the ever-rising healthcare needs and the incorporation of cutting-edge technologies into drug manufacturing. Hence, pharma stocks Eli Lilly (LLY), Green Thumb Industries (GTBIF), and Supernus Pharmaceuticals (SUPN) might be worth buying for returns this summer. Read more….

Do Wall Street Analysts Like Eli Lilly Stock?

Do Wall Street Analysts Like Eli Lilly Stock?

Eli Lilly stock has outperformed the broader market over the past year, and Wall Street analysts remain optimistic about the stock’s prospect.

Eli Lilly (LLY) vs. Novo Nordisk (NVO): Which Pharma Stock Is Driving Long-Term 2024 Profits?

Eli Lilly (LLY) vs. Novo Nordisk (NVO): Which Pharma Stock Is Driving Long-Term 2024 Profits?

The pharmaceutical market is poised for rapid expansion due to rising global medical needs and increasing integration of technologies in drug discovery and development. Amid this, let’s analyze Eli Lilly (LLY) and Novo Nordisk (NVO) to determine which pharma stock will drive long-term profits in 2024. Read more to find…

1 'Strong Buy' Dividend Stock to Buy and Hold

1 'Strong Buy' Dividend Stock to Buy and Hold

Discover why Eli Lilly is considered a 'strong buy' as it capitalizes on the growing demand for diabetes and obesity treatments, backed by its robust financial performance and promising future prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

Eli Lilly (LLY) or Pfizer (PFE): Which Stock Can Surge From Earnings?

Amid increasing healthcare spending, breakthroughs in genomics and personalized medicine, and the adoption of new technologies, the pharma industry is booming. So, let’s analyze Eli Lilly (LLY) and Pfizer (PFE) to determine which pharma stock will surge from their first-quarter earnings. Read on to find out.

Navigate to Success With These 4 Pharma Stocks to Buy

The pharmaceutical industry is expanding due to increased demand for healthcare products and technological advancements. Therefore, fundamentally strong pharma stocks Kamada (KMDA), Hypera (HYPMY), Eli Lilly (LLY) and Sanofi (SNY) might be ideal additions to your portfolio. Read on.

2 Obesity Treatment Stocks Morgan Stanley Likes More than Novo Nordisk

While Novo Nordisk's Wegovy currently dominates the obesity treatment market, Morgan Stanley sees more upside potential for LLY and AZN stocks going forward.

3 Mega-Cap Stocks That Could Replace Tesla in the 'Magnificent Seven'

As Tesla stock continues to underperform - now down more than 22% year-to-date - here are 3 mega-cap companies worthy of replacing the beleaguered EV giant in the elite group of mega-cap stocks known as the Magnificent Seven.

Get all your
news in one place.

100's of premium titles.
One news app.

It's Not Too Late to Buy Eli Lilly Stock. Here's Why.

J.P. Morgan thinks sales of weight-loss drugs could exceed $100 billion by 2030. That's good news for Eli Lilly, which is now the largest pharma company by market capitalization and the 9th-biggest S&P 500 stock. Here's why LLY stock looks poised to put on even more weight in the months…

Eli Lilly & Co. (LLY) Pre-Earnings Moves: Buy or Watch?

Eli Lilly (LLY) saw steady growth in its last reported quarter, driven by sales from its popular diabetes drug Mounjaro. The stock has had an impressive run over the past year. However, will the momentum be sustained following its upcoming earnings release scheduled for tomorrow? Read on.

Top 3 Smart Pharma Picks for Good Investments

As global medical needs and technology evolve, the pharmaceutical industry is expected to thrive. Therefore, fundamentally strong pharma stocks Eli Lilly (LLY), AstraZeneca (AZN) and GSK (GSK) might be ideal additions to your portfolio. Read on.

What’s the Best 2024 Pharma Stock Buy Among These 3 Stocks?

The pharma industry's potential for sustained growth is reinforced by an aging population, escalating healthcare demands, and the increase in chronic diseases. Therefore, let’s assess the fundamentals of pharma stocks Eli Lilly (LLY), Johnson & Johnson (JNJ), and Abbvie (ABBV) to determine the most promising choice for the current year….

Iron Condor Alert: LLY Stock Could Net 40% In 4 Weeks

Eli Lilly (LLY) is showing elevated implied volatility with an IV Percentile of 98%, and that could mean it’s a good time for an iron condor trade.

Top 4 Pharma Picks for January 2024 Growth

The pharmaceutical industry’s future is increasingly promising, spurred by a rise in healthcare expenditure amid escalating chronic and rare disease cases and a burgeoning aged population. The industry's bright outlook is also strengthened by consistent forays into research and development. Against this backdrop, quality pharma stocks Pacira BioSciences (PCRX), Eli…

Analyzing 3 Pharma Stocks for Year-End Gains?

The pharma industry is well-positioned for expansion owing to growing healthcare spending and the adoption of cutting-edge technologies to develop new drugs. Amid this backdrop, let’s analyze the investment prospects of fundamentally strong pharma stocks Eli Lilly (LLY), Teva Pharmaceutical (TEVA), and Johnson & Johnson (JNJ) for year-end gains. Read…

1 … 8 9 10 11

People

Dipanjan BanchurSince

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

365,502 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play